CAMBRIDGE, Mass.--(BUSINESS WIRE)--RaNA Therapeutics, a leading biotech developing a new class of revolutionary RNA-targeted medicines, today announced RaNA's CEO, Ronald Renaud, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:00 a.m. EST. Management will also present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016, at 2:40 p.m. EST. Both conferences will take place at the Waldorf Astoria in New York City.
The presentations will be webcasted and available in the Media Center of RaNA's website, www.ranarx.com. A replay of the webcast will also be archived for up to 30 days on RaNA's website following the conference.
To schedule a partnering meeting with RaNA Therapeutics’ management, contact Business Development at email@example.com.
About RaNA Therapeutics
RaNA Therapeutics is a leading biotechnology company committed to the development of next generation RNA-targeted medicines that selectively upregulate gene expression to increase endogenous protein levels for therapeutic benefit. The company was founded by preeminent global leaders who pioneered the relationship between lncRNA and chromatic modifiers as well as breakthrough oligonucleotide technologies. RaNA’s mission is to improve the lives of people suffering from serious life-altering diseases by creating precision medicines that can change the course of their condition. RaNA’s technology has broad therapeutic potential to treat a wide range of diseases, including rare genetic disorders. The company has current lead programs in Spinal Muscular Atrophy and Friedreich’s Ataxia. For more information about the company and its platforms, please visit www.ranarx.com.